Guggenheim Downgrades Altimmune (NASDAQ:ALT) to Neutral

Altimmune (NASDAQ:ALT) was downgraded by equities research analysts at Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, MarketBeat Ratings reports.

A number of other equities analysts also recently commented on ALT. The Goldman Sachs Group started coverage on Altimmune in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 target price for the company. B. Riley reiterated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research note on Thursday, March 28th. Finally, HC Wainwright dropped their price objective on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, April 1st.

Altimmune Stock Up 2.4 %

Shares of NASDAQ ALT opened at $6.55 on Monday. The business has a 50 day moving average price of $9.24 and a two-hundred day moving average price of $7.61. Altimmune has a fifty-two week low of $2.09 and a fifty-two week high of $14.84. The firm has a market cap of $464.36 million, a PE ratio of -3.97 and a beta of 0.05.

Altimmune (NASDAQ:ALT) last released its earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.02. The company had revenue of $0.04 million during the quarter. Altimmune had a negative net margin of 20,780.75% and a negative return on equity of 44.77%. On average, analysts anticipate that Altimmune will post -1.52 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

Several large investors have recently modified their holdings of the stock. SG Americas Securities LLC lifted its stake in Altimmune by 63.1% during the third quarter. SG Americas Securities LLC now owns 43,086 shares of the company’s stock valued at $112,000 after buying an additional 16,661 shares in the last quarter. Miracle Mile Advisors LLC acquired a new position in Altimmune in the 3rd quarter worth approximately $44,000. Barclays PLC grew its position in Altimmune by 62.0% during the 3rd quarter. Barclays PLC now owns 180,409 shares of the company’s stock worth $470,000 after purchasing an additional 69,014 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Altimmune during the 3rd quarter valued at $40,000. Finally, WealthPlan Investment Management LLC purchased a new stake in shares of Altimmune in the third quarter valued at $31,000. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.